Targeting NLRP3: DFV890 and Beyond скачать в хорошем качестве

Targeting NLRP3: DFV890 and Beyond

NLRP3 stands at the forefront of innate immunity, acting as a molecular sensor for a large array of sterile danger signals. When activated, it orchestrates the assembly of the NLRP3 inflammasome complex, releasing the cytokines IL-1β and IL-18 and triggering proinflammatory, pyroptotic cell death. Over the past decade, the role of IL-1β-driven inflammation has become increasingly appreciated across a spectrum of diseases—from cardiovascular conditions and gout to cancer—fueling an intense search for oral NLRP3 inhibitors as transformative therapies for numerous indications. In this Flash Talk, Angela MacKay will present Novartis’s NLRP3 drug discovery program including the discovery of DFV890 (developed by IFM-Tre) which is currently in clinical studies. Starting from a high throughput screen to identify phenotypic pathway inhibitors and building subsequent understanding of targeting the protein itself, enabled the creation of a broad medicinal chemistry program looking for drug molecules to target both peripheral diseases and the central nervous system. 00:00 Welcome and Introduction 9:24 Drug Hunter Platform - Structure Search 11:45 Presentation 50:18 Q&A If your company doesn’t have a subscription yet, reach out here to inquire about access: https://drughunter.com/plans Recorded on December 4th, 2025, as a Drug Hunter Flash Talk. Sign up to be notified of future sessions here: https://drughunter.com/flash-talk-ser... Sign up for our free newsletter here: https://drughunter.com/newsletter-sig...